|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
The concomitant use of USP28 and p53 to predict the progression of urothelial carcinoma of the bladder.
|
31822365 |
2020 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results were compared to existing data (i.e., other series of AA-associated UC and IARC TP53 database).
|
28477877 |
2017 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prior to this study, the p53 null phenotype was not well described in urothelial carcinoma of the bladder.
|
28342221 |
2017 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder.
|
29354488 |
2017 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine TERT promoter mutation status as well as the expression of PAX8, GATA3, p63, p40, p53 and uroplakin III in 17 patients with the upper urinary tract sarcomatoid urothelial carcinoma.
|
28052688 |
2017 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to detect the deletions/duplication mutations in TP53 gene exons using multiplex ligation-dependent probe amplification (MLPA) method in the patients with transitional cell carcinoma (TCC).
|
26685928 |
2016 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study was designed to investigate the association between TP53 mutation patterns and recurrence patterns in upper urinary tract urothelial carcinoma (UTUC) patients.
|
27286260 |
2016 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to test whether p53 and Ki-67 immunostaining could improve urothelial carcinoma (UC) detection on urinary cytology.
|
27873391 |
2016 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our results provide evidence for RTK/RAS pathway activation and p53 deficiency as a combinatorial theranostic biomarker that may inform the progression and treatment of urothelial carcinoma.
|
25795707 |
2015 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of survivin, β-catenin and p53 expression in urothelial carcinoma.
|
26614845 |
2015 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of p53 on survival of upper urinary tract urothelial carcinoma: a systematic review and meta-analysis.
|
23357513 |
2013 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two bladder transitional carcinoma cell (TCC) lines, RT4 (wild-type TP53) and 5637 (mutated TP53), were used in this study.
|
24289605 |
2013 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Gemcitabine had distinct toxicogenomic effects in the bladder transitional carcinoma cell lines with two different TP53 mutations.
|
23053941 |
2012 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of p53 isoforms was also detected in a few other urothelial carcinoma cell lines and tumor cultures and in 4 out of 28 carcinoma tissues.
|
22669776 |
2012 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
CTD_human |
Specific-mutational patterns of p53 gene in bladder transitional cell carcinoma among a group of Iraqi patients exposed to war environmental hazards.
|
22929185 |
2012 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
The frequent presence of UroVysion FISH abnormalities, urothelial carcinoma in situ, and p53 positivity by immunohistochemistry in cases of urinary tract LELC suggests a similar pathogenesis to high-grade invasive urothelial carcinoma.
|
21383609 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of p53 in upper urinary tract urothelial carcinoma.
|
21811225 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and TP53 mutations have been recognized as key genetic pathways in the carcinogenesis of transitional cell carcinoma.
|
21106220 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of tumor suppressor p53 and pRb in urothelium by SV40 T antigen resulted in urothelial carcinoma, resembling human high-grade carcinoma in situ.
|
21388952 |
2011 |
|
Carcinoma, Transitional Cell
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Between January 1999 and December 2008, 275 patients who received six BCG intravesical instillations for NMIBC (transitional cell carcinoma) after transurethral resection were assessed for differences in outcomes according to the level of p53 overexpression.
|
21487231 |
2010 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to investigate the effects of these two antineoplastic drugs on the apoptotic index and cell cycle kinetics of urinary bladder transitional carcinoma cell lines with wild-type or mutant TP53 (RT4: wild type for TP53; 5637 and T24: mutated TP53).
|
20558835 |
2010 |
|
Carcinoma, Transitional Cell
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alterations in p53 represent a highly promising marker of disease recurrence and cancer specific mortality after radical cystectomy for urothelial carcinoma of the bladder.
|
19616250 |
2009 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine the prognostic value of p53 gene mutations and P53 overexpression for predicting the incidence of recurrence, progression and long-term survival of patients with transitional cell carcinoma (TCC) of the bladder.
|
18367096 |
2009 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder.
|
18997737 |
2009 |
|
Carcinoma, Transitional Cell
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, there was no association of p53 or CCND1 polymorphisms with UC risk.
|
18640142 |
2008 |